Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug ConjugateAndrew C. Phillips, Edward B. Reilly, Lise I. Loberg et al.|Molecular Cancer Therapeutics|2018Cited by 52